RESUMEN

Acute leukemias (ALs) are the most common cancers in pediatric population. There are two types of ALs: acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). Some studies suggest that the Renin Angiotensin System (RAS) has a role in ALs. RAS signaling modulates, directly and indirectly, cellular activity in different cancers, affecting tumor cells and angiogenesis. Our review aimed to summarize the role of RAS in ALs and to explore future perspectives for the treatment of these hematological malignancies by modulating RAS molecules. The database including Pubmed, Scopus, Cochrane Library, and Scielo were searched to find articles about RAS molecules in ALL and in pediatric patients. The search terms were "RAS", "Acute Leukemia", "ALL", "Angiotensin-(1-7)", "Pediatric", "Cancer", "Angiotensin II", "AML". In the bone marrow, RAS has been found to play a key role in blood cell formation, affecting several processes including apoptosis, cell proliferation, mobilization, intracellular signaling, angiogenesis, fibrosis, and inflammation. Local tissue RAS modulates tumor growth and metastasis through autocrine and paracrine actions. RAS mainly acts via two molecules, Angiotensin II (Ang II) and Angiotensin (1-7) [Ang-(1-7)]. While Ang II promotes tumor cell growth and stimulates angiogenesis, Ang-(1-7) inhibits the proliferation of neoplastic cells and the angiogenesis, suggesting a potential therapeutic role of this molecule in ALL. The interaction between ALs and RAS reveals a complex network of molecules that can affect the hematopoiesis and the development of hematological cancers. Understanding these interactions could pave the way for innovative therapeutic approaches targeting RAS components.

Asunto(s)

Angiotensina II , Leucemia-Linfoma Linfoblástico de Células Precursoras , Sistema Renina-Angiotensina , Humanos , Sistema Renina-Angiotensina/fisiología , Leucemia-Linfoma Linfoblástico de Células Precursoras/metabolismo , Leucemia-Linfoma Linfoblástico de Células Precursoras/patología , Angiotensina II/metabolismo , Leucemia Mieloide Aguda/metabolismo , Leucemia Mieloide Aguda/patología , Transducción de Señal , Angiotensina I/metabolismo , Neovascularización Patológica/metabolismo , Animales , Fragmentos de Péptidos/metabolismo

RESUMEN

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection has been a global challenge. The complicated forms of the Coronavirus Disease 2019 (COVID- 19) can evolve to multiple-organ failure, including several coagulopathies related to a sudden worsening of respiratory status. This article aimed to review studies about hematological and hemostatic laboratory disorders directly related to COVID-19 and to discuss how SARS-CoV- 2 causes these abnormalities. The coagulation cascade model is associated with both COVID- 19 and pulmonary involvement. Laboratory changes are relevant to evaluate the coagulation state - D-dimer, prothrombin time (PT), Activated Partial Thromboplastin Time (APTT), platelet count and fibrinogen. Pregnant women and patients in Extracorporeal Membrane Oxygenation (ECMO) need special attention. Prophylactic interventions for COVID-19 coagulopathy should consider patients at risk for thrombotic events and potential contraindications. The mechanisms exerted by SARS-CoV-2 that impairs hemostatic balance include endothelial injury, inflammation, and activation of the immune and complement systems. For diagnosis of coagulopathy, mainly D-dimer, but also PT, APTT and FDP, should be evaluated in COVID-19 patients. Intervention possibilities vary between low-molecular-weight heparin (LMWH) and Unfractionated Heparin (UFH). Until now, there is sufficient evidence that acutely-ill patients with risk factors for coagulopathies will benefit from thrombophylaxis during hospitalization and post-discharge, but not all patients.

Asunto(s)

COVID-19 , Heparina de Bajo-Peso-Molecular , Cuidados Posteriores , Femenino , Heparina , Humanos , Alta del Paciente , Embarazo , SARS-CoV-2

RESUMEN

Objectives: There are few studies in the literature correlating metabolic alterations with prognostic factors in breast cancer. The aims of this study were to evaluate serum levels of total cholesterol, HDL, LDL, triglycerides and fasting glucose, weight, body mass index and blood pressure, and relate them to prognostic factors (stage, lymph node involvement, histological grade, estrogen and progesterone receptors, ki-67 and Her2/neu) in patients with breast cancer. Methods: A retrospective study was conducted in Mastology Service of the Discipline of Gynecology and Obstetrics/Oncologycal Research Institute (IPON) of the Universidade Federal do Triângulo Mineiro (UFTM). We evaluated 100 patients with breast cancer treated at Mastology Clinic (surgical and/or clinical treatment). Serum levels of total cholesterol, HDL, LDL, triglycerides and fasting glucose, weight, body mass index, blood pressure, staging, lymph node involvement,histological grade and immunohistochemical panel (estrogen and progesterone receptors, ki-67 and HER-2/neu) were recorded. Data were expressed as the mean ± standard deviation, and the values were compared by using Student's t-test. P-values less than 0.05 were considered statisticallysignificant. Results: Histological grades 1 and 2 were significantly correlated with higher HDL serum levels (p=0.02). Higher levels of triglycerides were found more frequently in grade 3, and highest weight was related to Ki-67 positive, but only with a trend towards significance (p=0.07). Conclusion: HDL can be related to prognosis in breast cancer.

---

Objetivos: Há poucos estudos na literatura relacionando alterações metabólicas com fatores prognósticos em câncer de mama. Os objetivos desse estudo foram avaliar os níveis séricos de colesterol total, HDL, LDL, triglicérides e glicemia de jejum, peso, índice de massa corporal e pressão arterial, e relacioná-los com fatores prognósticos (estadiamento, envolvimento linfonodal, grau histológico, receptores de estrógeno e progesterona, ki-67 e Her2/neu) em pacientes com câncer de mama. Métodos: Um estudo retrospectivo foi realizado no Serviço de Mastologia da Disciplina de Ginecologia e Obstetrícia e Instituto de Pesquisa em Oncologia (IPON) da Universidade Federal do Triângulo Mineiro (UFTM). Nós avaliamos 100 pacientes com câncer de mama tratadas no Serviço de Mastologia (tratamento clínico e/ou cirúrgico). Níveis séricos de colesterol total, HDL, LDL, triglicérides e glicemia de jejum, peso, índice de massa corporal, pressão arterial, estadiamento, envolvimento linfonodal, grau histológico e painel imuno-histoquímico (receptores de estrógeno e progesterona, ki-67 e Her2/neu) foram registrados. Dados foram expressos em média ± desvio padrão, e os valores foram comparados utilizando-se o test t de Student. Valores de p menores que 0,05 foram considerados estatisticamente significativos. Resultados: Graus histológicos 1 e 2 foram relacionados significativamente com níveis séricos mais altos de HDL (p=0,02). Níveis mais elevados de triglicérides foram encontrados maisfrequentemente em tumores grau 3, e peso mais alto foi relacionado com positividade de Ki-67, mas apenas com tendência à significância (p=0,07). Conclusão: Níveis séricos de HDL podem estar relacionados ao prognóstico em neoplasia maligna de mama.